Dr. Richard Finn on PD 0332991 Plus Letrozole in ER-Positive Breast Cancer

onclivetv has 407 videos Subscribe Here

Description: Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, describes results from a phase II study that examined PD 0332991, an oral selective inhibitor of cyclin-dependent kinase 4/6, in combination with letrozole as a first-line treatment for postmenopausal women with metastatic ER-positive breast cancer.

To view more coverage from SABCS, visit
Shared By : onclivetv
Posted on : 09/03/13
Added : 4 years ago
Category : Breast Cancer

More From onclivetv

Nothing found.